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Targeting Lifestyle Change
in Patients With Depression*
James A. Blumenthal, PHD
Durham, North Carolina
Depression is widely recognized as having significant im-
plications for both mental and physical health. More than 1
in 5 adults suffer from major depression (MDD) at some
point in their lifetimes, and estimates are even higher for
patients with coronary heart disease (CHD). Approximately
20% of patients suffer from MDD after a myocardial
infarction (MI), and an additional 20% might experience
elevated depressive symptoms without meeting diagnostic
criteria for MDD. Depression is associated with poorer
quality of life and increased medical expenditures and
healthcare use. In addition, depression is one of the leading
sources of disability in the United States and is associated
with greater absenteeism and lowered work productivity.
According to the World Health Organization, depression
will soon become the second leading cause of disability-
adjusted life years, after only CHD.
See page 622
There also is a growing body of published data that
have documented the association of depression with
adverse health outcomes, particularly in patients with
CHD. Numerous studies from multiple research teams
have reported that depression is associated with a 2- to
4-fold increase in risk for death and nonfatal CHD events
among patients with a variety of cardiac conditions, includ-
ing recent MI, coronary disease requiring surgical revascu-
larization, stable and unstable angina, and chronic heart
failure (1–3). As a result of these findings, the American
Heart Association commissioned a Scientific Advisory
Panel to evaluate the risk with depression in CHD patients
(4). Although recognizing that there was no direct evidence
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this paper to disclose.that screening for depression leads to improved outcomes,
the Panel concluded that—because of the overwhelming
evidence for the association of depression with worse
prognosis—assessment of depression was important with
the goal of “targeting those most in need of treatment and
support services.”
One of the most critical issues now facing clinicians is
how to best treat depressed cardiac patients. Current rec-
ommendations for depression treatment typically involve
pharmacotherapy, usually with a selective serotonin re-
uptake inhibitor (SSRI), although treatments with tricyclic
antidepressants, benzodiazepines, and combined therapies
are also prescribed (5). It has been estimated that approxi-
mately 50% of patients will have a clinical “response” to
treatment (i.e., a 50% reduction in symptoms), whereas
many patients will require augmented treatment with 1
ntidepressant agents (6). However, many patients do not
espond to antidepressant medications or experience untow-
rd side effects. Indeed, although data are limited, results
rom several randomized controlled trials of antidepressants
n cardiac patients have provided negative or equivocal
ndings. For example, the SADHART (Sertraline Against
epression and Heart Disease) trial was a randomized,
ouble-blind, placebo-controlled, 24-week trial of sertraline
or MDD among patients hospitalized for acute MI (7).
mprovement in depressive symptoms among participants
reated with sertraline was observed only in a subset of
atients with more severe depression; there was no differ-
nce between sertraline and placebo in the full sample. The
tudy was not powered to examine clinical outcomes. A
econd study (SADHART-CHF [Sertraline Against De-
ression and Heart Disease in Chronic Heart Failure] trial)
onfirmed the safety of sertraline among patients with
hronic heart failure, but sertraline did not reduce depressive
ymptoms any more than placebo (8). Moreover, partici-
ants treated with sertraline had no better clinical outcomes
ompared with those receiving placebo. The MIND-IT
tudy (Myocardial INfarction and Depression-Intervention
rial) also failed to demonstrate improvement in either
epressive symptoms or cardiac outcomes with antidepres-
ant treatment (9). In one of the few positive trials, the
REATE (Canadian Cardiac Randomized Evaluation of
ntidepressant and Psychotherapy Efficacy) study (10) re-
orted that depressive symptoms and remission rates were
mproved with citalopram compared with placebo, whereas
o differences in depressive symptoms were observed be-
ween patients receiving interpersonal therapy and clinical
anagement compared with patients receiving clinical man-
gement alone. The sample was too small to examine
linical outcomes, however. Meta-analyses of randomized,
ontrolled trials of antidepressant medications in cardiac
atients generally have reported no significant differences
etween antidepressant medication and placebo controls,
ut the authors still encouraged the use of antidepressant
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with medication (11,12).
One of the problems in developing effective treatments
for depression in cardiac patients is that the mechanisms
underlying the association between depression and worse
outcomes are not fully understood. A number of potentially
interrelated biobehavioral pathways have been studied, al-
beit often individually. Depressive symptoms have been
linked to autonomic nervous system dysregulation, vascular
endothelial dysfunction, abnormal inflammatory processes,
and maladaptive health behaviors (13). Indeed, the Heart
and Soul study noted that, among a variety of health
behaviors, physical inactivity was especially important (14).
Furthermore, there is mounting evidence that patients who
exhibit a worsening of depression over time seem to be at
especially increased risk for death or other adverse out-
comes, including nonfatal MI or cardiac-related hospital
stays (15,16). It remains unclear whether depression is
causally related to worse outcomes or whether depression is
simply a marker for more severe CHD or some other factor
associated with worse outcomes.
In this issue of the Journal, Ye et al. (17) seek to examine
his question by prospectively studying the relationship
etween depressive symptoms and nonfatal MI or all-cause
ortality in a subset of participants in the REGARDS
Reasons for the Geographic And Racial Differences in
troke) study. The REGARDS study is a population-based,
ongitudinal study of 30,000 African-American and white
en and women 45 years designed to determine the
easons for the higher incidence of stroke mortality in the
outheastern “stroke belt” region of the United States and
mong African Americans (18). Individuals were identified
rom commercially available lists of residents and were
ecruited with an initial mailing followed by telephone
creening calls. The present study was limited to 4,676
articipants with a history of CHD at baseline and complete
ata. Over a median follow-up period of 3.8 years, 125 of
38 (19.6%) participants with elevated depressive symptoms
xperienced a clinical event, compared with 657 of 4,038
16.3%) participants without elevated depressive symptoms.
fter adjustment for medical comorbidities, medications,
nd lifestyle factors, the association of depression and worse
linical outcomes was no longer statistically significant, and
he authors emphasized the importance of lifestyle factors in
xplaining the prognostic value of depression and CHD and
n guiding intervention efforts to reduce the elevated risk of
epression in cardiac patients.
The authors are to be congratulated for their contribution
o the published literature with this interesting analysis of a
arge and important dataset. Several important limitations
f the study should be acknowledged, however. As with
any substudies in which the variables under investigation
re of secondary importance to the parent study, the
ssessment measures were not optimal, and only a limited
umber of potential mediators were examined. Depression
as assessed by a seldom-used 4-item self-report measure of epressive symptoms that might not accurately classify
epression in all patients, while the 4 behavioral factors
elied on brief measures of self-reported alcohol use, med-
cation adherence, smoking, and physical activity. This lack
f precision might help to explain the lower-than-expected
ates of depression in this CHD population and also some
nexpected results, such as trends for better outcomes in
atients with high alcohol consumption and poor medica-
ion adherence. Smoking and physical activity explained a
ubstantial proportion of the association of depression and
he combined endpoint of MI and death, leading the
uthors to recommend smoking cessation and increasing
hysical activity in this population.
These lifestyle recommendations should come as little
urprise to readers of the Journal. Cigarette smoking is not
ncommon in patients with MDD (19), and patients who
ontinue to smoke, despite having CHD, might be engaged
n a highly maladaptive effort to treat their depression.
imilarly, a number of cross-sectional and observational
tudies have shown that physical inactivity is associated with
epression. For example, in the Alameda County Study,
amacho et al. (20) measured activity level and depressive
ymptoms of subjects in 1965, 1974, and 1983. Compared
ith men and women who reported higher activity levels,
hose who were inactive at baseline were at greater risk for
igher depression scores at the first follow-up. Participants
ho increased their physical activity level between 1965 and
974, however, were at no greater risk for depression in
983 than those who were active throughout the period.
onversely, those who became more inactive by 1974 were
ore likely to have higher depression scores in 1983
ompared with those who maintained a high level of
hysical activity. Of course, observational studies are limited
n that it cannot be determined whether people are inactive
ecause they are depressed or whether they are depressed
ecause they are inactive.
The effect of exercise on depression now has been
xamined in over 2 dozen randomized trials and has been
he topic of several meta-analyses and systematic reviews
21,22). Existing studies vary substantially in size, type of
ontrol group, methodological rigor, length of follow-up,
nd type of exercise. In a recent Cochrane review (21), the
rimary analyses were limited to 25 clinical trials comparing
xercise treatment with no treatment or a control interven-
ion. There were large, clinically meaningful improvements
n depressive symptoms associated with exercise in compar-
son with controls (standardized mean difference  0.82,
5% confidence interval: 1.12 to 0.51), which was
omewhat diminished when the analyses were limited to
hose trials with intention-to-treat analyses and blinded
utcome assessments. In addition, when analyses were
onducted among the 5 trials that collected long-term
ollow-up data, the effects of treatment were slightly weaker,
onsistent with a moderate clinical improvement (standard-
zed mean difference  0.44, 95% confidence interval:
0.71 to 0.18).
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of 101 CHD patients (25), now have compared exercise
with antidepressant medication. In these studies, exercise
training resulted in significant reductions in depressive
symptoms that were greater than placebo and comparable or
even superior to antidepressant medications. For example,
in the UPBEAT (Understanding the Prognostic Benefits of
Exercise and Antidepressant Therapy) study (25), after 4
months of treatment, scores on the Hamilton Rating Scale
for Depression were 3.3 points lower among exercisers
compared with patients receiving placebo, whereas the
average score was 1.7 points lower in patients receiving
sertraline compared with placebo. Furthermore, exercise
was even more effective in reducing clinical depression in
the subset of patients who were diagnosed with MDD at
study entry. Although the sample was small, 40% of
patients with MDD at the time of randomization were
remitted at the end of 4 months of exercise, compared
with 10% of those who received sertraline and none of the
patients who received placebo. A recent substudy from the
HF-ACTION trial (Heart Failure: A Controlled Trial
Investigating Outcomes of Exercise Training) (26) also
found exercise to be superior to guideline-based usual care
in reducing depressive symptoms in over 2,300 heart failure
patients.
So what is the take-home message? The term “cardiovas-
cular vulnerable patient” has been used to describe patients
susceptible to acute coronary events on the basis of plaque,
blood, or myocardial characteristics (27,28). It now has
become clear that depression is another of those character-
istics that also increases the vulnerability of CHD patients
to adverse events. In their report, Ye et al. (17) provide
support for the prognostic importance of elevated depres-
sive symptoms in CHD patients. Moreover, by identify-
ing smoking and physical inactivity as mediators of the
relationship between depression and adverse health out-
comes, they remind us of the value of promoting healthy
lifestyle changes and specifically smoking cessation and
exercise training to improve clinical outcomes in this
vulnerable population.
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